(Q40747003)

23 September 2017

A novel somatostatin conjugate with a high affinity to all five somatostatin receptor subtypes (English)

1 reference

23 September 2017

Ulrich Wulbrand

1

1 reference

23 September 2017

Martin Feldman

2

1 reference

23 September 2017

Andreas Pfestroff

3

1 reference

23 September 2017

Hans-Cristophe Fehman

4

1 reference

23 September 2017

Jin Du

5

1 reference

23 September 2017

Jukka Hiltunen

6

1 reference

23 September 2017

Marcela Marquez

7

1 reference

23 September 2017

Rudolf Arnold

8

1 reference

23 September 2017

Jan-Erik Westlin

9

1 reference

23 September 2017

Sten Nilsson

10

1 reference

23 September 2017

Anders R Holmberg

11

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

23 September 2017

5

1 reference

inferred from page(s)

published in

Cancer

1 reference

23 September 2017

94

1 reference

23 September 2017

4 Suppl

1 reference

23 September 2017

1293-1297

1 reference

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

23 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

Somatostatin and its receptor family

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

Somatostatin Half-Life: A Case Report in One Healthy Volunteer and a Three Month Follow-Up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

Improved analogs and novel delivery systems for somatostatin octapeptides.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

Multiple actions of somatostatin in neoplastic disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

Treatment of malignant endocrine pancreatic tumors with a new long-acting somatostatin analogue, SMS 201-995.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

Molecular biology of somatostatin receptor subtypes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

Somatostatin receptor activation of cellular effector systems

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

Characterisation of a cell line (LCC-18) from a cultured human neuroendocrine-differentiated colonic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

Isolation of glucagon-secreting cell lines by cloning insulinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

Somatostatin analogs for diagnosis and treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

Tamoxifen and somatostatin affect tumours by inducing apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

Somatostatin-14 and its analog octreotide exert a cytostatic effect on GH3 rat pituitary tumor cell proliferation via a transient G0/G1 cell cycle block.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

Somatostatin and the immune and haematopoetic system; a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

Therapeutic potential of octreotide in the treatment of liver metastases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

Therapeutic response to somatostatin analogue, BIM 23014, in metastatic prostatic cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10299

7 January 2021

Identifiers

DOI

10.1002/CNCR.10299

1 reference

23 September 2017

1 reference